Walden Biosciences

Walden Biosciences is a clinical-stage biotechnology company based in Cambridge, Massachusetts, relentlessly focused on developing first-in-class, highly-targeted, disease-modifying therapies for individuals living with kidney disease. Founded by world-renowned experts in renal disease, the company applies a dynamic, systems-based approach to understand kidney disease biology and advance a pipeline of novel medicines that directly target the kidney. Walden's work addresses both rare and prevalent forms of kidney disease, a condition affecting more than 1 in 7 American adults. The company launched in 2020 with a $50M Series A and has since grown its pipeline and raised over $126M in total funding.